2,4-双-(2-氨基-嘧啶-4-基)-苯酚 | 477726-77-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2,4-双-(2-氨基-嘧啶-4-基)-苯酚
• 英文名称: BMI-1026
• 英文别名: 2,4-Bis-(2-amino-pyrimidin-4-yl)-phenol；4-(2-Aminopyrimidin-4-yl)-6-(2-aminopyrimidin-4(3H)-ylidene)cyclohexa-2,4-dien-1-one；2,4-bis(2-aminopyrimidin-4-yl)phenol
• CAS: 477726-77-5
• 化学式: C₁₄H₁₂N₆O
• 分子量: 280.289
• InChiKey: WVOLVWGMFQNPHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  124
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  、 MOM-Cl NaH 、 苯乙酮 、 、 sodium ethanolate 、 盐酸胍 、 四氢呋喃 在 氮 、 二氯甲烷 、 crude product 、 甲醇 作用下， 以 乙醇 、 水 为溶剂， 反应 41.0h， 生成 2,4-双-(2-氨基-嘧啶-4-基)-苯酚
  参考文献：
  名称：

  Inhibitors of protein kinase for the treatment of disease

  摘要：

  本发明部分涉及使用苯酚和羟基萘基化合物调节蛋白激酶功能的方法。该方法包括使用表达蛋白激酶的细胞。此外，本发明还描述了使用本发明所识别的化合物预防和治疗生物体中与蛋白激酶相关的异常情况的方法。此外，本发明涉及苯酚和羟基萘基化合物以及包含这些化合物的药物组合物。

  公开号：

  US20030208067A1

文献信息

• METHOD FOR REMOVING SENESCENT CELL, AND METHOD FOR PREPARING SENESCENT CELL
  申请人：The University of Tokyo

  公开号：EP3878470A1

  公开（公告）日：2021-09-15

  Solutions to the problem of the invention are a method for selectively killing or removing a senescent cell, substance identification, and a method for purifying a senescent cell. Specifically, the invention includes an agent for removing a senescent cell, which is a drug for removing an in vivo senescent cell, the agent containing an inhibitor for glutaminase as an active ingredient, and a pharmaceutical composition containing the agent. The invention further includes a method for preparing a senescent cell, including the following steps (a) to (c): (a) synchronizing a cell with the G2 phase; (b) activating an intracellular p53 protein in the cell synchronized with the G2 phase; and (c) inhibiting polo-like kinase 1 (PLK1) activity in the cell treated in the step (b).

  解决本发明问题的方法是一种选择性杀死或清除衰老细胞的方法、物质鉴定和纯化衰老细胞的方法。具体来说，本发明包括一种去除衰老细胞的药剂，它是一种去除体内衰老细胞的药物，该药剂含有谷氨酰胺酶抑制剂作为活性成分，以及含有该药剂的药物组合物。本发明还包括一种制备衰老细胞的方法，包括以下步骤(a)至(c)：(a)使细胞同步进入 G2 期；(b)在同步进入 G2 期的细胞中激活细胞内 p53 蛋白；(c)抑制在步骤(b)中处理过的细胞中多聚样激酶 1 (PLK1) 的活性。
• INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE
  申请人：LG Biomedical Institute

  公开号：EP1412327A2

  公开（公告）日：2004-04-28
• PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER
  申请人：ArQule, Inc.

  公开号：US20200155521A1

  公开（公告）日：2020-05-21

  The present application is drawn to methods of treating a cell proliferative disorder, such as a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising at least one of Compound 1, Compound 2, and Compound 3, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, and at least one second therapeutic agent or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein the cell proliferative disorder is treated.
• [EN] INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA PROTEINE KINASE DESTINES AU TRAITEMENT D'UNE MALADIE
  申请人：LG BIOMEDICAL INST

  公开号：WO2002096867A2

  公开（公告）日：2002-12-05

  The present invention is directed in part towards methods of modulating the function of protein kinases with phenol- and hydroxynaphthalene-based compounds. The methods incorporate cells that express a protein kinase. In addition, the invention describes methods of preventing and treating protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to phenol- and hydroxynaphthalene-based compounds and pharmaceutical compositions comprising these compounds.